Skip to main content
. 2022 Aug 27;13(3):942–954. doi: 10.1016/j.apsb.2022.08.015

Figure 5.

Figure 5

The antitumor activity of DOTAP/CHOL-OVA, DOTAP-OVA and SA@DOTAP-OVA. (A) Schematic diagram of the immunotherapy regimen. (B–F) Tumor growth of each mouse in different groups. (G) Growth of tumor volume in different groups of mice. Data are presented as mean ± SD (n = 6). ∗P < 0.005, ∗∗∗P < 0.01. ns, not significant. (H) Tumor weight in different groups of mice after the therapy (mean ± SD, n = 6). ∗P < 0.05, ∗∗∗P < 0.01. (I,J) FACS analysis of OVA-specific CTL proliferation in the tumor (mean ± SD, n = 3). ∗∗∗P < 0.01.